NASDAQ:LMAT LeMaitre Vascular (LMAT) Stock Price, News & Analysis $81.04 -0.20 (-0.25%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$81.10 +0.06 (+0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LeMaitre Vascular Stock (NASDAQ:LMAT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LeMaitre Vascular alerts:Sign Up Key Stats Today's Range$79.00▼$81.6050-Day Range$79.77▼$85.7552-Week Range$71.42▼$109.58Volume126,468 shsAverage Volume101,135 shsMarket Capitalization$1.83 billionP/E Ratio40.93Dividend Yield0.99%Price Target$97.83Consensus RatingHold Company Overview LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts. Read More LeMaitre Vascular Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreLMAT MarketRank™: LeMaitre Vascular scored higher than 60% of companies evaluated by MarketBeat, and ranked 398th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingLeMaitre Vascular has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageLeMaitre Vascular has only been the subject of 1 research reports in the past 90 days.Read more about LeMaitre Vascular's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.86% Earnings GrowthEarnings for LeMaitre Vascular are expected to grow by 11.86% in the coming year, from $1.94 to $2.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LeMaitre Vascular is 40.93, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.09.Price to Earnings Ratio vs. SectorThe P/E ratio of LeMaitre Vascular is 40.93, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.Price to Earnings Growth RatioLeMaitre Vascular has a PEG Ratio of 2.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLeMaitre Vascular has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LeMaitre Vascular's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.11% of the outstanding shares of LeMaitre Vascular have been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in LeMaitre Vascular has recently decreased by 5.48%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldLeMaitre Vascular has a dividend yield of 0.98%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthLeMaitre Vascular has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of LeMaitre Vascular is 40.40%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 36.87% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.Read more about LeMaitre Vascular's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.11% of the outstanding shares of LeMaitre Vascular have been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in LeMaitre Vascular has recently decreased by 5.48%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.82 News SentimentLeMaitre Vascular has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for LeMaitre Vascular this week, compared to 5 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,556,857.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of LeMaitre Vascular is held by insiders.Percentage Held by Institutions84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LeMaitre Vascular's insider trading history. Receive LMAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter. Email Address LMAT Stock News HeadlinesLeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Hold" from BrokeragesJuly 27, 2025 | americanbankingnews.comInvestors in LeMaitre Vascular (NASDAQ:LMAT) have seen stellar returns of 208% over the past five yearsJuly 17, 2025 | finance.yahoo.comChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system tracks breaking AI news and shows when to trade.📈 AI-backed. Beginner-friendly. Results proven.August 2 at 2:00 AM | Timothy Sykes (Ad)LeMaitre Vascular, Inc. (LMAT) Balance Sheet - Yahoo FinanceJuly 12, 2025 | finance.yahoo.comLeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025July 8, 2025 | globenewswire.comLMAT LeMaitre Vascular, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comLeMaitre Vascular: Scaling Nicely As Global Demand BuildsJune 17, 2025 | seekingalpha.com1 Small-Cap Stock with Exciting Potential and 2 to Keep Off Your RadarJune 16, 2025 | finance.yahoo.comSee More Headlines LMAT Stock Analysis - Frequently Asked Questions How have LMAT shares performed this year? LeMaitre Vascular's stock was trading at $92.14 at the beginning of 2025. Since then, LMAT shares have decreased by 12.0% and is now trading at $81.04. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular, Inc. (NASDAQ:LMAT) posted its quarterly earnings data on Thursday, May, 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by $0.02. LeMaitre Vascular's quarterly revenue was up 12.0% on a year-over-year basis. Read the conference call transcript. Does LeMaitre Vascular have any subsidiaries? LeMaitre Vascular subsidiaries include Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and others. Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's top institutional shareholders include Conestoga Capital Advisors LLC (7.10%), Copeland Capital Management LLC (4.38%), Congress Asset Management Co. (2.98%) and Envestnet Asset Management Inc. (1.35%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Trent G Kamke, Lawrence J Jasinski, John A Roush and Bridget A Ross. View institutional ownership trends. How do I buy shares of LeMaitre Vascular? Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/01/2025Record date for 5/29 Dividend5/15/2025Ex-Dividend for 5/29 Dividend5/15/2025Dividend Payable5/29/2025Today8/02/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LMAT CIK1158895 Webwww.lemaitre.com Phone(781) 221-2266Fax781-425-5049Employees490Year Founded1983Price Target and Rating Average Price Target for LeMaitre Vascular$97.83 High Price Target$110.00 Low Price Target$93.00 Potential Upside/Downside+20.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$1.98 Trailing P/E Ratio40.93 Forward P/E Ratio41.77 P/E Growth2.14Net Income$44.04 million Net Margins19.96% Pretax Margin25.78% Return on Equity13.53% Return on Assets9.78% Debt Debt-to-Equity Ratio0.48 Current Ratio16.49 Quick Ratio13.83 Sales & Book Value Annual Sales$226.26 million Price / Sales8.09 Cash Flow$2.38 per share Price / Cash Flow34.01 Book Value$15.00 per share Price / Book5.40Miscellaneous Outstanding Shares22,594,000Free Float20,448,000Market Cap$1.83 billion OptionableOptionable Beta0.82 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:LMAT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LeMaitre Vascular, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LeMaitre Vascular With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.